Regeneron, Tocilizumab, Dexamethasone, Eli Lilly, Glaxosmithkline, Astrazeneca Antibody, Antibody Covid-19 Therapy, Recovery Trial, Seronegative, Vir Biotechnology

Regeneron, Tocilizumab

Regeneron antibody therapy helps Covid patients lacking antibodies – study

Regeneron antibody trial results translate into six fewer deaths for every 100 patients lacking natural antibodies, with investigators confident in therapy's benefit

6/16/2021 1:45:00 PM

Regeneron antibody trial results translate into six fewer deaths for every 100 patients lacking natural antibodies, with investigators confident in therapy's benefit

The antibody therapy reduced the 28-day mortality of Covid-19 patients whose immune system did not mount an antibody response, shortened the hospital stay and reduced their chances of needing a ventilator.

Regeneron Pharmaceuticals Inc's Covid-19 antibody cocktail reduces deaths in hospitalised patients who have not mounted their own antibody response, a large British study published on Wednesday found.The therapy, REGEN-COV, has been granted emergency use authorisation for people with mild-to-moderate Covid-19 in the United States but results from the RECOVERY trial provide the clearest evidence of its effectiveness among hospitalised patients.

Germany's Social Democratic Party wins most seats in federal elections, preliminary official results show Tony Awards: ‘Moulin Rouge,’ ‘Inheritance,’ ‘Soldier’s Play’ Nab Top Prizes Long-Silent Facebook Friend Comes Out Of Woodwork With Post Asking About Insulating Windows

It found that the antibody therapy reduced by a fifth the 28-day mortality of people admitted to hospital with Covid-19 whose immune system had not mounted an antibody response, known as seronegative.The result translates into six fewer deaths for every 100 seronegative patients treated with the therapy, researchers said.

There was no discernible effect of the treatment on those who had generated natural antibody responses and were seropositive."People have been very, very sceptical, that any treatment against this particular virus would work by the time people get in hospital," Martin Landray, the joint chief investigator on the trial, told reporters.

"If you haven't raised antibodies of your own, you really would benefit from getting some," he said.The treatment also shortened the hospital stay of those who were seronegative and reduced their chances of needing a mechanical ventilator, Landray said.

Regeneron had previously said its treatment had shown enough promise in hospitalised patients to warrant continuing its trial. This data provides the first large-scale confirmation of that assertion.There were 9,785 patients hospitalised with Covid-19 who were randomly allocated to receive usual care plus the antibody combination therapy or just usual care, of which 30 percent were seronegative.

The RECOVERY trial also showed the steroid dexamethasone and Roche's arthritis drug Actemra (tocilizumab) cut deaths in hospitalised patients.While those treatments focus on inflammation caused by reaction to the coronavirus, Regeneron's therapy, which belongs to a class of biotech drugs called monoclonal antibodies, mimic natural antibodies the body produces to fight off the infection.

"This is the first time we've got one that's actually targeting the virus itself," Landray said, adding that it could be used along with the other treatments."It's not that you do one thing or another thing. These benefits are additive in these patients," he said.

Liz Cheney: 'I Was Wrong' In Opposing Gay Marriage In Past Social Democrats beat Merkel's bloc in German elections Covid’s Hidden Toll: One Million Children Who Lost Parents

Other similar treatmentsOther companies have been developing similar treatments.US emergency use authorization has been granted to antibody treatments developed by Eli Lilly and Co as well as by Vir Biotechnology Inc with GlaxoSmithKline Plc. Both are approved for use in mild-to-moderate cases.

On Tuesday, AstraZeneca said its antibody therapy had shown no evidence of protecting people from developing the disease following exposure, although other trials of its cocktail as a prevention or a treatment are ongoing.Landray said the RECOVERY results should give developers of other monoclonal antibody therapies optimism that they can also be used in some hospitalised patients.

"This opens up the possibility for many, many others," he said."People see a few negative trials and they say 'well that'll never work' and they opt out and go off and do something else. (But) this is very, very clear, the picture that we've got from this trial." 

Read more: TRT World »

Justice elusive 7 years after students abducted in Mexico

Several thousand students and political activists have marched through downtown Mexico City to demand authorities find out what happened to 43 teacher’s college students who disappeared in 2014

Regeneron Antibody Therapy Saves Lives Of Hospitalized Covid-19 Patients, Large U.K. Study FindsI am a London-based reporter for Forbes covering breaking news. Previously, I have worked as a reporter for a specialist legal publication covering big data and as a freelance journalist and policy analyst covering science, tech and health. I have a master’s degree in Biological Natural Sciences and a master’s degree in the History and Philosophy of Science from the University of Cambridge. Follow me on Twitter theroberthart or email me at Well The best decision I've made this year was investing in crypto and forex trading and earning from home, as professionals trade for me. With the help of pro_ElizabethD I've been earning great returns weekly, their is no way I’ll make loses!

Study: Nearly a quarter of COVID-19 patients developed new or long-term conditionsAbout 23% of COVID-19 patients have developed at least one 'persistent or new' medical condition more than four weeks after their initial diagnosis, according to a new study from FAIR Health. Why it matters: New post-COVID symptoms were discovered across different age groups. The five most common were pain, difficulty breathing, high cholesterol, malaise and fatigue, and high blood pressure, reports the New York Times.Stay on top of the latest market trends and economic insights with Axios Marke No no, it’s all in people’s heads. They’re lazy and they’re looking for any excuse not to work. They’re trying to scam benefits.

Data: Plumbers bask in post-COVID demand boom, pay tops $100K in some marketsPlumbers appear to be in especially high demand — with some states being more lucrative for the profession than others.

New Guidance Issued On Covid-19 Vaccines For People With CancerThe four-page guide answers common questions about Covid-19 vaccines for people with cancer and their caregivers. horrible

Boxing Star Teofimo Lopez Tests Positive for COVID, Championship Fight PostponedNoooooo!!!!! awwwwwwwwww lthomasnews

Colombia Protest Leaders Halt Demonstrations as Covid-19 Cases RageThe leaders of a protest movement that has rocked Colombia for seven weeks on Tuesday called off demonstrations amid a spike in Covid-19 cases that the government partly blames on the mass mobilizations Dr. Luc Montagnier reveals how Covid-19 is a lab accident He was awarded the 2008 Nobel Prize in Medicine for the identification AIDS.He currently works at University in China The Wuhan city lab has specialized in coronaviruses since the early 2000s For all those who are new to this working from home Bitcoin trading options Here's a little tip: Get a trusted Bitcoin expert and stick to her Alex_jnns01 Invest and play at similar times each day. Because : In times of chaos, your investment is your anchor to success Marching Strike of loacls in the eastern part of Dawei Tsp and Auk Kyauk Wap village in LaungLone Tsp in opposition of Genocidal Dictatorship. UnfetteredAccessForAids June15Coup WhatsHappeningInMyanmar